Auxo Firm Directory · Independent Research Profile

Revelstoke Capital Partners

Revelstoke Capital Partners describes a research-driven healthcare investment strategy focused on fragmented, high-growth markets. Its published criteria include control transactions, $50 million-$500 million of equity through the life of a platform investment, and target companies with strong management teams, recurring or nondiscretionary services, and organic growth opportunities.

Key takeaway

Revelstoke Capital Partners focuses on U.S.

healthcare services, healthcare technology, and health and wellness companies. It prefers control transactions and targets founder-, entrepreneur-, or physician-owned businesses with strong management teams, profitable unit economics, recurring or nondiscretionary services, and multiple organic-growth levers.[1][2][3][4][8][11]

What does Revelstoke Capital Partners invest in?

Revelstoke Capital Partners is a Denver-based private equity firm focused on healthcare services, healthcare technology, and health and wellness companies.

The firm operates under a structure identified in its regulatory disclaimer as including Revelstoke Capital Management LLC and Revelstoke Capital Advisors LLC. The SEC Form ADV identifies Revelstoke Capital Management LLC as the legal name and Revelstoke Capital Partners as the primary business name.[1][11][12]

Revelstoke describes a research-driven, thematic sourcing strategy. It identifies healthcare themes, maps industries, dedicates resources to target segments, leverages its network, and acts with urgency to complete investments.

The firm also publishes a control-oriented investment approach and a target of $50 million-$500 million of equity through the life of a platform investment.[4]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Published size criteriaPublicly stated range
Lower published point$50MILLION
Upper published point$500MILLION

Published criteria: Revelstoke targets $50 million-$500 million of equity through the life of a platform investment.[4]

What should a business owner evaluate before considering a transaction with Revelstoke Capital Partners?

An owner evaluating Revelstoke should compare the company’s characteristics with the firm’s stated preference for control transactions and its criteria for founder-, entrepreneur-, or physician-owned businesses, recurring or nondiscretionary services, profitable unit economics, customer diversification, and organic-growth levers.

The proposed ownership structure, governance rights, rollover equity, management incentives, leverage parameters, valuation methodology, and expected ownership horizon should be confirmed directly. The firm’s Portfolio Transformation Group publicly describes resources across strategy, operations and finance; strategic partnerships and procurement; technology; talent; responsible investment; and capital markets, so the scope of any assigned support should also be clarified.[3][4]

01

What ownership percentage and governance rights would Revelstoke typically seek in a platform investment

The firm states a preference for control transactions, making the proposed control structure and governance rights important points to clarify.[4]
02

What equity amount would be allocated to the company, and how would platform equity be distinguished from add-on capital

Revelstoke publishes a $50 million-$500 million equity target through the life of a platform investment and separately reports platform companies and add-on acquisitions.[4][10]
03

What is the expected investment or ownership horizon, and what circumstances could lead to a sale, recapitalization, or continuation transaction

The official investment criteria page does not state an expected investment holding-period range or ownership-duration standard.[4]

What companies does Revelstoke Capital Partners target?

Revelstoke prefers control transactions and seeks founder-, entrepreneur-, or physician-owned companies with strong management teams. Its stated criteria also include sustainable organic growth, profitable gross margins and unit economics, recurring or nondiscretionary services, customer diversification, and multiple levers for double-digit organic growth.

The firm targets $50 million-$500 million of equity through the life of a platform investment.[4]

Revelstoke states that it has a singular focus on high-growth markets within fragmented healthcare services, healthcare technology, and health-and-wellness sectors.[4]

Revelstoke states that its target geography is the United States, while also considering select international opportunities.[4]

Revelstoke’s public transaction record distinguishes platform companies from add-on acquisitions. In a September 17, 2025 announcement, the firm reported completion of its 200th acquisition since founding, comprising 30 platform companies and 170 add-on acquisitions.

The published criteria describe equity through the life of a platform investment; owners should clarify how a proposed opportunity would be classified and funded within that structure.[4][10]

The official portfolio page identifies current and exited investments including AOM Infusion, CEI Vision Partners, Claremedica, Connext Global Solutions, Fast Pace Health, Griffin Concierge Medical, Omega Systems, Rarebreed Veterinary Partners, The Care Team, Upstream Rehabilitation, and Vi Labs.[5]

On December 4, 2025, Revelstoke announced that portfolio company The Care Team acquired select hospice and palliative care operations from Traditions Health in Illinois, Indiana, Ohio, and Virginia.

On September 30, 2025, Revelstoke announced an investment in Griffin Concierge Medical, described as the tenth platform investment from Revelstoke Capital Partners Fund III. On April 15, 2025, it announced that it completed a recapitalization of AOM Infusion, described as the ninth Fund III investment. On January 16, 2025, it announced a strategic investment in Omega Systems, described as the eighth Fund III investment.

In its September 17, 2025 transaction milestone announcement, Revelstoke announced completion of its 200th acquisition since founding, comprising 30 platform companies and 170 add-on acquisitions and totaling over $15 billion of enterprise value.[6][7][8][9][10]

What is not clear from Revelstoke Capital Partners's public investment criteria?

The official disclaimer states that featured investments are illustrative and do not constitute a complete list of current and prior investments; it states that a complete list is available upon request.

The AOM Infusion transaction announcement states that the terms of that transaction were not disclosed.

The official investment criteria page does not state an expected investment holding-period range or ownership-duration standard.[4][8][11]

Questions to ask when evaluating Revelstoke Capital Partners as a buyer or investment partner

What ownership percentage and governance rights would Revelstoke typically seek in a platform investment?
The firm states a preference for control transactions, making the proposed control structure and governance rights important points to clarify.[4]
What equity amount would be allocated to the company, and how would platform equity be distinguished from add-on capital?
Revelstoke publishes a $50 million-$500 million equity target through the life of a platform investment and separately reports platform companies and add-on acquisitions.[4][10]
What is the expected investment or ownership horizon, and what circumstances could lead to a sale, recapitalization, or continuation transaction?
The official investment criteria page does not state an expected investment holding-period range or ownership-duration standard.[4]
How would rollover equity, management incentives, earn-outs, and seller notes be handled?
The published company criteria emphasize strong management teams, but the cited criteria do not specify the terms of these instruments.[4]
What debt or leverage parameters would apply to the proposed transaction?
The cited company-criteria material establishes the transaction preference and target characteristics but does not specify leverage parameters.[4]
Which Portfolio Transformation Group resources would be assigned to the company?
Revelstoke describes in-house resources across strategy, operations and finance, procurement, technology, talent, responsible investment, and capital markets; the allocation for a specific company should be confirmed.[3]
How much acquisition integration and de-novo expansion would be contemplated for the company?
Revelstoke’s public record includes platform companies and add-on acquisitions, while the scope of activity for a particular investment should be clarified.[10]
Which healthcare subsectors and geographic markets are currently prioritized for new platform investments?
The firm states a U.S. target geography with select international opportunities and a broad focus across fragmented healthcare sectors; current priorities should be confirmed for the proposed opportunity.[4]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Official website / firm overview
  3. Services / capabilities
  4. Investment strategy
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. Transaction / portfolio evidence
  11. Public disclosure information
  12. SEC filing / regulatory record
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.